Investment analysts at StockNews.com began coverage on shares of Aethlon Medical (NASDAQ:AEMD – Get Free Report) in a note issued to investors on Thursday. The brokerage set a “sell” rating on the medical equipment provider’s stock.
Separately, HC Wainwright lowered their price target on Aethlon Medical from $10.00 to $7.00 and set a “buy” rating on the stock in a report on Monday, June 24th.
Aethlon Medical Price Performance
Aethlon Medical (NASDAQ:AEMD – Get Free Report) last announced its quarterly earnings results on Wednesday, August 14th. The medical equipment provider reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.10. During the same period in the prior year, the company posted ($1.30) EPS. Sell-side analysts forecast that Aethlon Medical will post -1.13 EPS for the current year.
About Aethlon Medical
Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.
Read More
- Five stocks we like better than Aethlon Medical
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Advance Auto Parts Eyes Long-Term Growth Despite Q2 Hurdles
- What is Forex and How Does it Work?
- Toll Brothers Stock Up on Q3 Beat: Luxury Homes Drive Growth
- Why Are Stock Sectors Important to Successful Investing?
- 4 No-Brainer Stocks to Hold This Fall for Steady Gains
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.